a2 Milk Stockouts Shifted China Users and Reset the Rebuild Cost

The a2 Milk Company reported FY26 revenue of NZ$1,974.9 million, up 12.4 percent, while continuing-operations net profit after tax fell 5.8 percent to NZ$207.5 million and underlying NPAT rose 7 percent to NZ$235.8 million. China-label infant formula sales dropped 14 percent after fourth-quarter stockouts that pushed users to rivals, and ASX-listed shares closed down 3.26 percent at A$6.53.

Total reported NPAT including discontinued operations landed near NZ$111 million. The company still declared ordinary dividends of 21 cents per share plus a NZ$300 million special dividend, yet the lasting customer shift and gradual recovery plan now set the real terms for investors.

The Numbers That Define FY26

Continuing operations tell a clearer story than the headline attributable figure used by some wires. Revenue reached NZ$1,974.9 million. EBITDA slipped 2.5 percent to NZ$284.4 million; underlying EBITDA (ex-a2 Pōkeno losses and transformation costs) climbed 5.4 percent to NZ$307.6 million. Gross margin compressed 3.4 points to 47.7 percent on mix, higher milk costs, one-off disruption expenses and under-utilised Pōkeno capacity.

Basic EPS from continuing operations was 28.6 cents; underlying EPS reached 32.5 cents. Operating cash conversion sat at 68 percent. Inventory rose as the company built raw materials for English-label insourcing and new China-label lines. Full detail sits in the FY26 annual report highlights and financials.

China Stockouts Handed Users to Rivals

China-label IMF revenue fell 14 percent to NZ$544.3 million. First-half sales still grew 6.5 percent. Second-half sales collapsed 33 percent once stock ran short in the fourth quarter. Drivers included strong third-quarter demand, freight delays linked to Middle East disruption, Synlait production backlogs, longer release times and extra customs steps.

Market share in Mother & Baby Stores dropped from 4.2 percent (MAT March) to 2.1 percent in the fourth quarter. Domestic online share fell from 4.6 percent to 1.8 percent. A large share of existing users switched brands rather than wait. Brand sentiment later rebounded, yet the company itself frames recovery as gradual across FY27.

• China & Other Asia revenue still rose 11.2 percent to NZ$1.45 billion on English-label and other nutritionals strength.
• English-label IMF jumped 23.2 percent to NZ$788.3 million via CBEC, O2O and Vietnam.
• Other Nutritionals surged 59.9 percent to NZ$216.1 million on kids, seniors and new paediatric lines.
• USA revenue climbed 28.6 percent to NZ$178.7 million and reached EBITDA breakeven in the second half.

The stockouts were temporary. The customer losses look stickier. That second-order shift is why management now spends on win-back gifts, loyalty, distributor support and two new China-label SKUs aimed at lower-tier cities and organic.

Cash Came Back While Guidance Softened

The board paid an interim ordinary dividend of 11.5 cents and declared a final ordinary of 9.5 cents, for 21 cents total and a roughly 74 percent payout of continuing NPAT. It also paid the foreshadowed special dividend of NZ$300 million, or 41.36 cents per share. Combined ordinary and special returns reached NZ$453 million.

The Board declared a special dividend totalling $300 million in June 2026 equating to 41.36 cents per share. In total, the Company declared $453 million in ordinary and special dividends in FY26, providing a significant cash return to shareholders.

Chair Pip Greenwood made that point in the annual report. Net cash still closed at NZ$784.5 million after the Pōkeno investment and higher inventory. Fortress finances remain intact. Debt-to-equity is negligible.

FY27 guidance is more cautious. Management expects mid-single-digit revenue growth, an EBITDA margin near 15 percent, and a first half that is materially softer than the prior corresponding period as China-label offtake rebuilds only gradually. IMF sales overall are seen as broadly flat with FY26. Capital expenditure is pegged around NZ$70 million.

Pokeno Becomes the Control Bet

The a2 Pōkeno facility acquisition closed in the prior year and delivered two existing China-label registrations. SAMR later approved amendments so the products can carry the a2 brand. The site is now central to the plan: launch two new China-label formulas in the first half of FY27, insource English-label a2 Platinum production from Synlait in the same window, and reach EBITDA breakeven at the plant including one-off costs.

Capital spend at Pōkeno hit NZ$51.6 million of a multi-year programme near NZ$100 million. Manufacturing headcount more than doubled. The logic is simple. Greater vertical control should cut the exact availability failures that just cost market share. Chair Greenwood called FY26 a landmark year for the China growth strategy and supply-chain transformation precisely because of this asset.

Whether the new capacity and registrations translate into regained share fast enough to offset the marketing outlay remains the open question. An update is due at the November annual meeting.

English Label and Diversification Carried Growth

While China-label struggled, the rest of the portfolio advanced. Liquid milk rose 21.8 percent overall. Australia liquid-milk value share reached 11.7 percent. Lactose-free hit a record 22.6 percent share in its segment. USA household penetration and distribution points both expanded; the brand now ranks among the top-ten liquid-milk names there and is among the fastest growing.

Vietnam English-label IMF sales grew 200 percent as weighted distribution jumped from 1 percent to 43 percent. Products launched in recent years contributed more than half of FY26 sales growth. The medium-term ambition of NZ$2 billion revenue remains on the table for FY27, though the China-label leg of that bridge is still marked “work in progress.”

These engines kept group revenue and underlying profit rising even as the highest-margin China-label channel contracted. They also dilute pure China risk, yet the China-label franchise still sets brand perception and premium pricing power across Asia.

How the Market and GF Score See It

On the ASX, A2M finished the results day at A$6.53, down 3.26 percent, after ranging between A$6.10 and A$6.66. The 52-week range runs from A$4.88 to A$9.97. Analyst targets average near A$8.07. OTC-traded ACOPF has hovered near US$4.95.

GuruFocus places its GF Value intrinsic estimate of $4.49 against that price, implying roughly 10 percent overvaluation. The GF Score sits at 88 out of 100, with perfect 10/10 financial strength and momentum scores, solid profitability and growth ranks, and a fair-to-stretched valuation rank. Debt is minimal and the Altman Z-Score is high. Trailing P/E has run above its five-year median.

Income investors can point to the 2.69 percent yield near a two-year high and a moderate payout. Dividend growth, however, has been flat in recent ordinary years before the special. No premium gurus or insiders have shown recent activity in the name according to the same data set.

The valuation debate now turns less on the last twelve months and more on how expensive the share rebuild becomes. Soft first-half margins, extra marketing and any delay in Pōkeno ramp all pressure the multiple that the market will pay for the underlying growth engines.

Rebuild Math and the Next Twelve Months

Management’s four-pillar plan covers rebuilding trust (traceability tool already live), driving recruitment (gifts and loyalty), supporting the trade ecosystem, and launching the two new China-label products. Early sentiment scores have improved sharply. Distributor support is described as solid. New-user conversion rates have returned toward historical levels. Offtake is still expected to recover only gradually across the full year.

That timeline means the first half of FY27 carries the heaviest mix and cost headwinds. English-label momentum is also expected to need extra marketing support. The USA business must defend its new breakeven status. Any further supply hiccup would compound the customer-recovery bill.

Investors who focus only on the special dividend and the fortress balance sheet miss the second-order ledger. The stockouts did not merely defer sales; they transferred habitual users. Winning them back costs real money and time. Pōkeno is the structural answer the company has chosen. Execution on the new registrations, the Platinum insourcing and the win-back campaigns will decide whether FY27 looks like a soft transition year or a prolonged reset.

The company results and reports page and the full annual report remain the primary sources for the numbers. Further detail on the brand and markets sits on the a2 Milk official company site. The cash return is real. The share rebuild is the larger and longer variable now in play.